Biolab Farmacêutica partners with George Medicines to exclusively offer innovative technology for hypertension control
The drug GMRx2 has already been approved by the FDA (Food and Drug Administration) in the USA. Biolab to seek regulation from ANVISA
Biolab Farmacêutica, one of Brazil's ten largest companies, has signed an exclusive licensing and marketing agreement in Brazil for GMRx2, an innovative combination in a single pill containing three active ingredients for the treatment of hypertension - telmisartan, amlodipine and indapamide. Single-pill combinations of three low-dose antihypertensive drugs can improve hypertension control. A key issue for any combination product is the contribution of each component to efficacy, adherence and tolerability. The drug is the first with this combination and, once approved by ANVISA, should be strategically integrated into the cardiology portfolio of the company, which is the leader in the segment in Brazil. The owner of the technology is George Medicines, which specializes in the development of advanced-stage drugs.
National and international studies and guidelines point out that most patients with hypertension need two or more drugs to adequately control their blood pressure. GMRx2 offers patients efficacy and practicality since, according to an article published in The Lancet, it enables blood pressure to be reduced and controlled right from the start of treatment. The study, which involved 1,300 participants, showed that low-dose GMRx2 (Triple Combination) of telmisartan, amlodipine and indapamide provided clinically significant improvements in blood pressure reduction compared to double combinations and was well tolerated. This drug provides a new therapeutic option for the management of hypertension and its use may result in a substantial improvement in blood pressure control in clinical practice.
"The partnership with biopharmaceutical company George Medicines reinforces Biolab's strategic presence in the cardiovascular segment. The drug, which will be submitted for regulatory approval in Brazil, represents an important innovation in the treatment of hypertension. With a consolidated structure and a strong medical presence, we are prepared to expand access to effective and safe solutions for the health of the population," says Fabio Amorosino, CEO of Biolab Farmacêutica.
Another innovation is that, by combining three drugs in a single pill, the drug improves adherence to treatment by simplifying the patient's routine. In addition, its lower doses offer fewer side effects, maintaining the same clinical efficacy as treatment with the same drugs in separate, higher doses, guaranteeing safety without compromising results in blood pressure control.
"This partnership in Brazil further strengthens our global commercial strategy for GMRx2 and comes shortly after the product's regulatory approval in the United States and licensing agreements for the US, Canadian, Mexican, Colombian and Central American markets. Through the partnership with Biolab, we have the opportunity to significantly advance cardiovascular care in Brazil," Mark Mallon, CEO of George Medicines.
"The statistics confirm the priority given to heart disease. Around 30% of the adult Brazilian population lives with hypertension. Thus, the partnership with George Medicines represents a unique opportunity to offer innovation and better blood pressure control to millions of people, completing our range of treatments for the chronic condition," adds the CEO of Biolab Farmacêutica.
About Biolab
Promoting a future with a better quality of life requires a tireless search for safe and innovative treatments. That's why Biolab, a Brazilian pharmaceutical company founded in 1997 and with an international presence, invests in research and partnerships to overcome the growing challenges of health.
With almost 4,000 employees and one of the largest sales forces in the country, the company stands out among Brazil's largest pharmaceutical companies. In 2025, it was recognized by LinkedIn Top Companies as one of the 15 best places to work in Brazil, based on criteria such as growth opportunities, skills development, diversity and stability.
Biolab operates in various specialties, such as dermatology, gynecology, orthopedics, gastroenterology, pediatrics, clinical medicine and the central nervous system, as well as being a leader in cardiology. The Biolab Genéricos, Avert Humana and Avert Biolab Saúde Animal business units contribute to a portfolio of more than 500 products.
Biolab is constantly growing. It has three production units, as well as a modern manufacturing complex under construction. And it doesn't stop there: in Canada, it is the first Brazilian pharmaceutical company with a research center and has acquired the company Exzell Pharma to expand its borders.